These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


240 related items for PubMed ID: 29042204

  • 21. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.
    Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA.
    Hum Vaccin Immunother; 2013 Jul; 9(7):1399-406. PubMed ID: 23571174
    [Abstract] [Full Text] [Related]

  • 22. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, Durand C, Hervé C, Descamps D.
    Vaccine; 2013 Nov 19; 31(48):5745-53. PubMed ID: 24091311
    [Abstract] [Full Text] [Related]

  • 23. Seroprevalence of HPV 6, 11, 16 and 18 and correlates of exposure in unvaccinated women aged 16-64 years in Puerto Rico.
    Ortiz AP, Tortolero-Luna G, Romaguera J, Pérez CM, González D, Muñoz C, González L, Marrero E, Suárez E, Palefsky JM, Panicker G, Unger ER.
    Papillomavirus Res; 2018 Jun 19; 5():109-113. PubMed ID: 29555601
    [Abstract] [Full Text] [Related]

  • 24. Human Papillomavirus Antibody Levels Following Vaccination or Natural Infection Among Young Men Who Have Sex With Men.
    Chow EPF, Fairley CK, Zou H, Wigan R, Garland SM, Cornall AM, Atchison S, Tabrizi SN, Chen MY.
    Clin Infect Dis; 2022 Aug 25; 75(2):323-329. PubMed ID: 34971362
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial.
    Kreimer AR, Sampson JN, Porras C, Schiller JT, Kemp T, Herrero R, Wagner S, Boland J, Schussler J, Lowy DR, Chanock S, Roberson D, Sierra MS, Tsang SH, Schiffman M, Rodriguez AC, Cortes B, Gail MH, Hildesheim A, Gonzalez P, Pinto LA, Costa Rica HPV Vaccine Trial (CVT) Group.
    J Natl Cancer Inst; 2020 Oct 01; 112(10):1038-1046. PubMed ID: 32091594
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. High prevalence of oral human papillomavirus infection in Fanconi's anemia patients.
    de Araujo MR, Rubira-Bullen IR, Santos CF, Dionísio TJ, Bonfim CM, De Marco L, Gillio-Tos A, Merletti F.
    Oral Dis; 2011 Sep 01; 17(6):572-6. PubMed ID: 21332606
    [Abstract] [Full Text] [Related]

  • 32. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
    Faust H, Toft L, Sehr P, Müller M, Bonde J, Forslund O, Østergaard L, Tolstrup M, Dillner J.
    Vaccine; 2016 Mar 18; 34(13):1559-1565. PubMed ID: 26896686
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
    Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group.
    Clin Vaccine Immunol; 2015 Apr 18; 22(4):361-73. PubMed ID: 25651922
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Seroprevalence of human papillomavirus 6, 11, 16, and 18 in young primiparous women in Sao Paulo, Brazil.
    Rama CH, Villa LL, Pagliusi S, Andreoli MA, Costa MC, Thomann P, Longatto-Filho A, Eluf-Neto J.
    Int J Gynecol Cancer; 2010 Nov 18; 20(8):1405-10. PubMed ID: 21051985
    [Abstract] [Full Text] [Related]

  • 36. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
    Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, Zahaf T, Catteau G, Geeraerts B, Descamps D.
    Hum Vaccin Immunother; 2014 Nov 18; 10(8):2147-62. PubMed ID: 25424918
    [Abstract] [Full Text] [Related]

  • 37. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women.
    Petäjä T, Pedersen C, Poder A, Strauss G, Catteau G, Thomas F, Lehtinen M, Descamps D.
    Int J Cancer; 2011 Nov 01; 129(9):2147-57. PubMed ID: 21190190
    [Abstract] [Full Text] [Related]

  • 38. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
    Konno R, Dobbelaere KO, Godeaux OO, Tamura S, Yoshikawa H.
    Int J Gynecol Cancer; 2009 Jul 01; 19(5):905-11. PubMed ID: 19574783
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure.
    Coseo SE, Porras C, Dodd LE, Hildesheim A, Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Gonzalez P, Sherman ME, Jimenez S, Solomon D, Bougelet C, van Doorn LJ, Quint W, Safaeian M, Costa Rica HPV Vaccine Trial (CVT) Group.
    Sex Transm Dis; 2011 Oct 01; 38(10):976-82. PubMed ID: 21934576
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 12.